Editas Medicine (EDIT) 22 Feb 232022 Q4 Earnings call transcript

Good morning and welcome to Editas Medicine’s Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the Company’s request.

I would now like to turn the call over to Ron Moldaver, Investor Relations for Editas Medicine.

Sherry. you, Thank and XXXX everyone our quarter fourth Good call. welcome full-year conference and morning, to Earlier issued morning, and this we recent financial providing corporate results our update. a press release the two hours its today’s be call A after of replay approximately available completion. of on website our Investors will section After our the will we call Q&A. prepared remarks, open for

Private Company’s for reminder, those a and the most prospects plans file various our SEC make Litigation purposes as factors, Risk important As indicated XX-K, annual provisions forward-looking expectations, the Securities subsequent by in that a Harbor during section this of results with Forward-Looking Statements the Act filings. future we Factors these remarks Form statements call on of Safe recent result of the from about is XXXX. by discussed those as the updated differ may Reform report constitute under various our Actual of materially on including which

today only statement, forward-looking any as subsequent addition, In required forward-looking representing date. to our specifically any our update Except any upon change. by of views obligation of statements not revise or views any disclaim as if our views be relied we as law, even as and represent should

to Now, O’Neill. I our call will turn the over Gilmore CEO,

I’m Thank Officer; Medical and members everyone. Ron Executive you, and two Mei, good Chief our Chief Michelle Officer. joined other team, Financial by today morning, of our Baisong the Editas’ Robertson,

inherited proof-of-concept ex-vivo history approaches. for in human disease. AV year using Medicine’s landmark as team announced and a Editas in LCA-XX CasX was therapeutic EDIT-XXX we in-vivo data In chemical therapeutic year patients an delivered demonstrated our Last retinal both our in-vivo November demonstrating two proof-of-concepts

enrolment trial. we limited pause the tough our addressable In BRILLIANCE to in the to made due However, population decision patient

readout fetal to the clinical our study cell December levels we study continues cell clinically expression The of and that progress. correct safely X/X disease. autologous patients, data therapy sickle in RUBY hemoglobin anemia shared the to ex-vivo severe and human EDIT-XXX of could provided proof-of-concept drive in EDIT-XXX encouraging initial Phase from demonstrating sickle very meaningful disease

into move undertreated our life-saving goal these build on with untreatable or as to we delivering As will medicines we XXXX, to drive previously continue diseases. we patients towards of successes

you a of position in for our gene in-vivo last shared strategy many to month, Editas As we leader know, editing. as program

strategy, are of There three will here. underlying pillars I our recap which

focus First, and to disease develop or editing sharpened in-vivo while genome Thalassemia Beta discovery transfusion medicines, we our continuing for administered have TDT. severe sickle Dependent EDIT-XXX to cell

discovering therapies, cell month. continue our support and longer developing standalone but Shoreline our Cell Biosciences no iNK We to we cell partnered have are or to divested last therapy programs, Franchise

Additionally, to we divest platform our or seeking IRD are AAV and assets. program those terminated

XXXX. which sharpened cash focus talent, into discovery allowed headcount extended our us our reduced to runway and our XX% approximately Our by concentrate

and second are our strategic Turning engine to discovery strengthening capabilities. pillar, our technological we

We discovery enhancing our capabilities separate division the have split research of groups, into technology and drug each.

will care Under current therapeutic managing diseases. differentiate for our genome criteria, our the that serious allow will target from maximally selection new to standard targets we approach of select

maximize the that of commercial here a probability success. assets robust is pipeline regulatory build Our technical, goal of to and

Leadership to toolbox our Chief gene our Furthering is Officer platform internal innovation to enable Eaton Business Chief both would continue his component external a targeted addition execution group repair. role veteran via our spearhead clinical and delivery RPD technology in Technology new Bruce goals a in new targeted Our to achieving who, enhancing Bruce and is objectives. the on biotech focus editing business key under to gene will Officer, development. technology as

therapeutic other in cells targets our or work Within we lead begun and stem drug HSCs have discovery discovery in-vivo tissues. group, hematopoietic on

and our to a new CSO forward updating progress drug in this and future. work discovery our up group Our continues in-vivo I to search the look who search for head you will on

Finally, development. our is third in pillar business increase to an approach expanded strategic

through delivery discovery to will targeted and pursue objectives. and right In editing tandem, potential clinical will partnership internal execution gene of licensing in our drug we forward, we of to and combination the Going the leverage IP development continue to our and technologies portfolio in-licensing discussions. order out tools expedite complementary drive

plans Moving by to a our taking HSC shared new actions. last we position development for are under strategy, the we three hemoglobinopathies in leadership pursuing as month, therapeutics

sickle First, cell positive resources driver of data heavily RUBY invest the into X/X to clinical Phase thalassemia. EDIT-XXX The our treatment the development to we accelerate investment initial and from study a reallocated decision have our of for more EDIT-XXX. key beta clinical was of

and our XXX, journey of third, of patient to and as for of approach cell cells TDT. investing preconditioning are which or stem in-vivo both sickle diseases milder an well the approach the for leveraging Second as hematopoietic by we unique develop HSC, improve develop with and reduce editing live who cell burden forms currently and should differentiated patients

on discovery will administered genome other focused tissues. Beyond efforts in in-vivo development medicines hemoglobinopathies and be our editing

Turning from patients and safety our sickle Sentinel to of cell have parallel patients. begun of last dosing we month, data the completed the have RUBY strategy the clinic. the review disease update Since, of shared for additional we trial

and on On provide remain by remain year-end, year-end. the TDT, first certainly We and but dose EDIT-XXX ambitious this patient to provide in quarter track EDITHAL trial this trial the track goal. RUBY for dose we attainable update update by clinical XX on Phase from total X/X to an data on our an mid-year an at patients

in step a we strategy, execution. keenly I’m Taking back, our focused on and confident remained

our year. fourth forward redact on our Shoreline. updating We you building new strategy milestones look throughout are the quarter from of progress with our and execution our We the to upon the deal clinical and recently announced momentum during

will turn Medical I Chief Now our Baisong, call over the to Officer.

morning, Thank you, Gilmore. Good everyone.

data mentioned, EDIT-XXX. As the from Gilmore initial December, trial last presented RUBY we of

across clinically hematological two data who for follow-up cell improvement all had that first of first a significant the with severe the For five-months sickle patients disease, patient parameters. a showed

robust patients with a preliminary that potentially suggests Editas severe the These give benefit disease, in to cell sickle clinical for potential has has that the data long-term. can and clinical product candidate differentiation

of XX.X%, infusion. have four increase XX% sickle that symptoms. to fetal five-months normal more by pleased Specifically, see hemoglobin hemoglobin per infraction deciliter range than per deciliter XX.X the of that no may the into patient also where EBIT-XXX has patient total patient’s We threshold well cell gram were gram increased of Above hemoglobin to patients. fetal male the

Corpuscular as clinically evidence hemoglobin empirical cells cells, pg gram fetal per pan the exceeding prevent finally, level will sickle. red or distribution F-cells red increased with of pg cell the cellular those highly And Mean red hemoglobin blood hemoglobin gram the concentration fetal blood indicates XX and per XX.X XX% fetal to that meaningful threshold from considered was

promoted by utilize As we persistence of fetal fidelity, AsCasXXa sequence specific done hemoglobin. highlighted, action have is EDIT-XXX disrupt suppressor, of previously highly unique the to of that genes gamma-globin editing mimicking the of BCLXXA edit The mechanism the a binding engineered of nature hereditary a mechanism high enzyme.

of occlusive dependence patients. In patients, turn, this manner cell residing independent a be periodic high in events can and fetal in level and and stress, through of hemoglobin provides in in beta transfusion sustained every anemia that thalassemia the vessel sickle resolving sickle, a reduced,

sickle review of Since data, completed our for cell patients sentinel disease. RUBY initial trial launching the have safety the from we

we to sickle dosing of parallel we the patient to patients to now that have remain share safety by patients first We we dosing simultaneously favorable continue commenced a sequential that year-end. dose are two means dosing, can profile. and on we completing XX patients, pleased track multiple see After cell

encouraging, data. initial Our with clinical consistent data were preclinical very

in subsequent similar confident results we of see patients. replication will are We

We have said before is that disease events. categorized sickle than more by occlusive cell vessel just

symptoms other hemolysis, anemia, in result It other organ such fatigue, damage. stroke and can severe as

As treatment. improvement symptoms see for differentiation we more durable patients time, over continue potential to monitor longer and via term in we

last the focused I our team has rest Editas clinical year, execution. joining and Since management on sharpening of been

studies. We RUBY are in the those forward updating with the as pleased you EDITHAL trials EDIT-XXX of progress. Look to both momentum very and

I Now our our call to Michelle, to financials. the Financial turn Chief review will Officer, over

I fourth press for full-year quarter will earlier and refer our our items. opportunity to release this few I and of a financial to summary you XXXX. results briefly would you Thank morning, Baisong, review everyone. the for to issued like today a take good

XXst XXX XX, to XXXX. and cash, of cash December million Our $XXX equivalent marketable as December compared of were million as securities

existing and capital XXXX. our our to operating into expenses securities cash expect investment and fund marketable We cash, equivalent

is Revenue decrease by for recognized related XXXX. with XXXX is BMF. decrease approximately revenue in in mostly XX million This driven to XX compared collaboration our million agreement a to

XX of an G&A expenses legal in based decrease strategy and decreased The and offset was by increase year-over-year in XX net a XXXX. the in legal XXXX million decrease expenses in compensation. from to stock million

well as pausing manufacturing Editas increased a from advance the was XXXX. in in to related principally BRILLIANCE connection costs to EDIT-XXX incurred with XXXX expenses a XXX million financial in million The charge increase one-time million $XX Overall by strong in XXX trial. clinical and driven R&D incurred in enrollment remains position. as

our in-vivo said, and support our research Gilmore strategy provides into and our extends our and trials cash As shop XXXX. as discovery. of development advancing and continued to as resources This ethics ample runway well EDIT-XXX Hemoglobinopathy discovery other

call Gilmore. I that, with And back will hand to the

has and a two Thank clinical of joined a you, product. I one to has competitive which POCs, Michelle. In the deep since the Editas, the Company almost eight-months potential demonstrated be differentiated

business other of technologies development development, seller to developed therapy tissues, HSCs an business beginning. deal is of already through have in-vivo our shoreline we clinical addition, resources gene divest discovery external robust new the internal standalone strategy, reallocated Begun shared with of accelerate up new and and and our of development this our In toolbox building for and the just our the goal, and executed EDIT-XXX. editing editing complementary

we to our progress and Looking our transformation, you. our into look on XXXX, continuing strategy, sharing with executing forward

specific in-vivo, reminder, for a our discovery other CSO of discovery aligned a year include our tissues. editing new with our group, refocusing hiring advancing on the vision, strategic to HSC As objectives and expertise

XXXX, patients initial last plan following to On term trial. from the from patients on and the execute XXXX, which study that mid-XXXX dosed data development RUBY in we ongoing were updates the the the as year, of side, longer include the RUBY from clinical data end EDIT-XXX two well additional providing from will in as

providing patients addition, TDT EDIT-XXX patient the by for EDITHAL the XX and trial the in RUBY in trial for finally In dosing EDIT-XXX in this total data early year-end. EDIT-XXX TDT first our dosing by program quarter, year-end, EDIT

answer to for happy we questions you in and now. your very much are Thank you. Thank Editas, interest

comes [Operator Instructions] Joon Please with proceed. Truist Lee from question first Securities. Our

This morning. for Joon. [Mattie] good is on (Ph) Hi

on questions. expect and have Ultra. already made that So and they or a on XXXX, nature slick technology AsCasXXa mentioned have takers of patent I CasXXa have for related for two IDT you AsCasXXa, paper on the Do the mutations communication

you the similar from are different you. using how Thank is So, AsCasXXa Ultra? or that CasXXa

ask have couldn’t pose it. first to you I to may hear an your I actually Matthew, Well, question.

Sorry.

AsCasXXa for slick takers So, have technology? do and you expect you other or already some

would or Thank you, and I deal most we exclusive the in license which obviously in have EDIT-XXX that gave an our their derived iMac done, iNK Mattie. That Well, knock-in the recent what addition driven Shoreline, was agreement non-exclusive is say sleek AsCasXXa. to asset. technology and for platform, them for we additional license with that selling an oncology to or was

So example that are of think and licensing. on an we where as is I sleek AsCasXXa

then And interferences AsCasXXa. regard disputes have us IP there comfortable actually estate no freedom And or we to are with a AIP, the for your that gives around to operate. second very other around question

you very Thank much.

Citi. Semenkow Our Samantha Please is from with question proceed. next

Good questions. taking morning, for our thanks

could there specifically is expertise if I’m could when question, CSO, they be us what any wondering give for next appointed. are you looking experience in First you and or expectation your for

Samantha. very Thanks much,

number We in capabilities for are different of qualities future our a CSO. and looking

for We looking somebody clinic. the are developing experience drugs bringing in and who has into

the groups. for looking are expertise, We ability genomics to with complex and work

for are capabilities regulatory as the our to us important future will in and who probabilities looking the success, and Eaton, Chief targets team clinical driving target actually Officer, our the success. Officer the which therapeutic as including tissues of we combine commercial and and of leadership selection Chief the with probability Bruce somebody working in well technology number elements, has technical a we for of And Medical also collaborative of with Technology executive Baisong, help significant

happy with And with the the we progress timing, to I’m making. regard are

the best We I’m our happy discovery CSO timing is will you. talking driving on very our the you leadership which But in in on what have the is are that really making will interesting sure organization. tell depend that to forward Thank And group we that with choose the very candidates. for I the strategy we interim.

you Thank Okay. very much.

from question Stifel. Dae Ha with Gon Our next Please is proceed.

morning, good Clarification taking Hey questions. one for on then question thanks from our and the me clarification.

move forward think pivotal you into sufficient to kind patients filing Do it is XXXX. XX the by regulatory whether year-end dosing or that So, RUBY of is trial? for

it to if what just to to given Magenta you where milder the to your conditioning, when the you differentiation here, wanted for think perhaps for can thoughts And Thanks. then is comes you on it speak differentiation contemplate potential get direction the preliminary you updates? pertains And BD, areas can then of question guys. and on actually Jasper CD-XXX,

very much Gon. thanks Dae Yes,

So with regulatory important over data going coming to are agencies. to needs, generate that the FDA - very something of matter a and clinical XX, be be to just regulatory the regard that is that actually of will And with that other and lot year. planning actually the agreement is the we a regard with discussion we

Now differentiation. with regard and to milder conditioning

a ways looking are of of number I that. at think, there

actually it think the the thing about population. significantly eligible broadens I key patient conditioning is that milder

should are unfortunately how therapeutic it, significant going co-morbidities, long-term the using from result I severe from disease. just an their Current many extremely conditioning precluded And say, complications of which patients intervention. to is

to actually CD-XXX. conditioning think se, the about population substantially that doesn’t So is an that these from I benefit differentiated think, when mild patient broaden per actually you have to And therapies. piece important could be

advance regard of we broad differentiates eligibility will we something to milder we the is general and With are exploring and on of benefit that conditioning. be share sort more through able that actively approaches the development think to the to beyond how that patients we other as

Great. updates. Thanks for the

next & Phil Cowen is Nadeau from with Our Please Company. proceed. question

for the questions. taking Good progress morning. Congrats thanks on and our

on a First EDIT-XXX. couple

parallel design will RUBY trial a before and sense have will preliminary the do then in And that in patients number the dosing on TDT, the us, you of you can that In of as the follow-up to first to RUBY the that similar be mid-year sequential in be terms EDIT-XXX work? moving in two to update remind dosing? patients

those to Phil. our answer Baisong Chief to I’m questions. ask two going Thanks Medical Officer

Phil Thank question. you. Thank you, for your

the term data data Regarding data additional this the your dosed we share release, in longer the year share from we we number patient not and share time, first question year. but will dose will this multiple the year can middle what that of is the for last patient patient two

multiple started dosed sequential dosing and additional And of also addition them parallel sentinel been patients and not in we for the that, recess. enrolled of cell is been already be have And only the process have patients. some - the patient, the others in dosing dosing to edited but the we CDXX being

we trial and the So very the are with pleased confident of progress RUBY progress.

For your second question, can you repeat again?

Yes, sorry.

RUBY XXX two of the the same and is thalassemia before first to In terms be and design on the can dosing? move will parallel the as sequentially you patients that trial dosed

Yes.

details data. we the patients we we have So have when will sentinel share more more of will and

could that the then have when you begin testing And mild two regimen? you in when Great. milder could prior of do questions question, preconditioning, terms a a follow-up the sense move the Editas preconditioning clinic into

looking to Thank you mentioned of give sense some in you were technologies you. of you us then what bring think in-house. you Could you And complementary need? complementary terms development, second, business technologies,

Yes, to appropriate at we more will thanks regard actually the we able details time some more share very we the about talk you. have Phil. that With milder preconditioning, that future when in feel an to with much,

in-vivo our in to will of With regard technologies, And the targeted details across in again, that to the more about additional around targeted will be important able just general, obviously those approaches. technology focus, driving to the elements and looking future. advanced that share we delivery we two be complementary editing are and

taking for Thanks our questions. Perfect.

Thanks Phil. very much,

from proceed. is Bienkowski Please Rick with question next Our Fitzgerald. Cantor

the congrats on Hi Thanks progress taking morning. the and all here. everyone. questions Good for

the where like why I looks established? reasons undisclosed, question area that initial to be stem know on you indications an these and currently it gene target as it two the cells. than cells going of first highlight the the of but more are first editing in-vivo the could organ efforts why rather pipeline. are liver the delivering like editors discovery in-vivo this is advantageous initial are chose of you towards target my So methods the Could focus

by year? what of that there manufacturing can and limit to trying patient you could likely year, parallel for is the the I dosing or question, more understand of in to be here limitations XX second sickle that would guess dose trial. distributed really number of it patients important goal if over my the in half capacity for in then the a available I’m Are dosing And any cell if is patients evenly year-end weighted the be back or towards bed

questions. much very those for Thanks Rick

pipeline have while we of one pipeline. reason me our question, other focus several key indeed we we Let our HSCs tissues, about are aligns in-vivo about at to that disclosed. a HSCs, we looking with in-vivo is that did The talked it talk actually turn active the of which not is that which

It XX which EDIT-XXX simplified validated the or that human predominantly will those the a or actually we validated in disclosed having yet. focus HPPG however, somewhat have a haven’t AsCasXXa looking humanly target factor builds enzyme on are say, us we enables on and are I target the other our at and enzyme calculus promoter, success tissues to of in largely a really by essentially delivery. the but we

questions we in year. CMC you indeed, and limitations, But for the parallel our about enthusiasm both reallocated and the have there with editing and following invested community tell have regard your our plans limitations to to with actually could dosing. substantially disclosure supporting our more capital to do Turning new Baisong and second to not the probably strategy data

very Yes, Rick, question. yes, is that good sure. a

internally actually handle have the We manufacturing all with mentioned, as So, able a discussed CMC our strong beefing really working as and internal up partners. we capacity - handle capacities team CMC to before. be we Gilmore those CMC

really patient we a the we of strong over recruitment, terms last years. several have the In momentum see -

as So there. prospective have we patients enrolled, pleased in in number screening to patients are very of well being as we see the the

So, we confident the to goal XX very achieve are we by patient be will year-end. able

think previous previous weeks. think months you I you said I years, and meant when

Last several months well, sir. yes as

lot we And you. in initial and very enthusiasm Thank the disclosed from a December. XXX data of excitement Yes. Thanks much. when patients and investigators

you. thank Great,

Joel next proceed. Please Baird. is Beatty question from Our with

to surrounding [Jack so of Vertex is update ask thank based by Joel. of looking XXXX. for and much. time Thank the the course surrounding were I and it if Hi USPTO. litigation to CRISPR your decision IP dialing-in cell as or hoping beta there IP you light settlements provide taking dynamics the And XXXX February you it late IP for We so relates XXXX, in for to commercialize potential, an can therapy aCASX wondering you your is as and I relates competitor, CTXXXX early the questions, much Allen] CRISPR/CasX, as and CASX was thoughts thalassemia as of had any any sickle that guess the you it in I portfolio?

Thanks the broads Jack PTAB IP by obviously, was happy very very much, were that February. the question. for we upheld last the And

very is a key this time and I thing the delighted exciting that think, patients. is we for are

is for an updating to of appropriate with you and a our look we first CRISPR the agreement technology, Obviously, details time, time. to a enable the approval based an at the patients will be on medicine exciting serious very potentially This of the negotiated diseases. looking are advance -- we continuing that because for we

so Thanks much.

Thank you.

Please Oppenheimer. Our is Olson Jay proceed. from next question with

the for data of the community you talk feedback and their thank about trial? independent monitoring RUBY latest the update review for thanks questions. and from Can that your taking Hey you received any you

a second implications your allocation a any year? there or result expenses Thank as reprioritization capital of for question, you. strategy operating this then are portfolio And your process,

much. about release very IDMC Thank you parallel feedback dosing? want do Baisong, to the the for and talk you

continued sure. Yes, patients. Jay, IDMC Yes. for the from two Sentinel question. and and the data parallel the and The for Thanks, had dosing patients, the they dosing of reviewed agreed

to And regard for Baisong. OPEX to with going and capital then Michelle. implications Thanks the that to pass very allocation, much, I’m

Great. Hi, Jay.

back out So refocus We obviously XXXX. on were extend expenses, that. with but guidance able the runway into our don’t we to give strategy, cash can you into

further was and invest and our the that in in obviously to will million cash at trials advanced Given in of year, continue XXX the our invest clinical technology the balance continue CMC, to in-vivo platform. of and we EDIT-XXX, end both then

Great, thank Michelle. much Thanks you very very Thanks. much.

JP next Please Morgan. Our Brian proceed. question from is Cheng with

on collaboration. Hey guys provide this my your going for the to fairly prompted, that curious the with looks color if Gilmore, the can to on indications it the wide taking next well. morning. Bristol like how you the collaboration XX any is open programs you. factors are I’m thanks are call just color steps more Thank us and programs, that covering? some What were Bristol

Thanks Brian. very much,

the are very happy with actually We BMS collaboration.

one target that I opt-ins have we things driving the packages very providing think, believe been that the of around high-quality is nominations. that is I

there program covers But or alpha broad sway collaboration based is details on for is nature as the focused oncology and treatment agreement, be rather programs. more can Brian. a we disclosed I where haven’t think advances from and forthcoming, the of T-cells cell the And actually I you the The be. think the oncology target which to possibilities, the publicly. will likely of Thanks types BMS infer of

you Gilmore. Thank

Please is next RBC from question with Capital Issi Our proceed. Markets. Luca

question. on on a about patients are have on RUBY patients think Congrats flagging that by quick two prior is ones. XX follow-up so the becoming I year-end. Again, taking I may, if there the think How a required registrational. any will you actually Obviously registrational my have you color you’ll Thanks to I past question what that package? the be for have spoken appreciated. minimum potentially and the in progress. all circling Great. you’ve back based much Maybe trial is much now many

will deal is maybe and Thanks just LCA-XX you What on that exploring update you strategic there? much. broadly, moment? on in you give IRD the and then for ideal a can partner more an Gilmore are so option And what an be us ideal

for Luca, your Thanks question.

clarify. to wanted just So

XX patients a package. is by but of total from of ambitious, the have separate year-end. to dose attainable We registration That goal

number to regulatory As a engagement of a the registrational package, that that. patients earlier, a bit Gilmore finalize have data package, we to need mentioned and actually agency required will for with the

also worth part is all of in or application. that, data the It potency that the matrix on actually provide will the assay actually marketing we agreement because patients have be dosed adding matrix that will RUBY

question to for a particular your exploring options are a strategic would divestiture, second potentially regard interest IRD potential our ideal diseases and With interested ocular sponsor we AV actually in in be An delivery. partner and with divestitures. rare

is in we a complete being and But future the that progress partner in rare not restriction, but would make. retinal look an you forward ideal an be a us. development update we able expertise for disorders And the key on to their to

Got Thanks much. you. so

with from is Our Please America. proceed. of question next Greg Harrison Bank

good Thanks taking for the Hey, questions. morning.

reorganization First, data. just the discussed previously, but get it how cell. what on you note, to needs here I for cell to complete to are have you profile on has a sickle your another and need just what then And to wanted latest expectations ask to sickle in know wanted with really on, that? been with be thoughts else close know, the competitive happen show, to you

the to sharing in in at hemoglobin updates initial we And end this cell very would middle year. forward clinical are and and patients the forward in anemia. data resolution to of consistent in impacts, set we preclinical regard and subsequent for the robust which our see and were the by with that of replication confident, we look were the data, fetal data, data looking on both effects demonstrating with So sickle encouraged again

And completed we largely then to regard with have that reorganization, reorganization.

person reorganization about think scientific have in functional execution critical traits, good forward. good moving But we discovery already leading organization looking our I and new element the leadership the our that already outstanding little qualities that the development, officer. the I of talked is other strategy. are the chief is a for the hiring the of bit are that of is of forward in the news components have characteristics,

is questions. for that the Great, taking thanks helpful.

Please Zhu Yanan question is next Fargo. Wells proceed. Our with

have point trial, Have patient questions. That the sickle for process third reach the with carried the commercial a is the And plan if discussion with of you a sickle process you process out process. manufacturing cell at with of for thanks And the that to some and of first along path kind bridging a date cell trial XXXs kind it Hi, currently. the dozed EDIT-XXX? out lastly, is in grade And the is generation the what question. regulator forward from the not yet? do about needed i.e.,

much just Baisong of very the Thanks Yanan. update? sort capitulate you could

Yes.

too. for first let will thanks So manufacturer the I the your answer get question, will questions. question you in Gilmore I about two two and there

actually So, appropriate. when will path dose package discuss - registration, parallel patient yes, as is start data for that regarding more we registration that and and then the the we authority we And the of did -- data we the share third forward, and we for time the mentioned started dosing health patients. required will finalize with to

and to will be actually that dosing support are marketing RUBY much XXX certainly we have area, in to we patients regard the matrix successful very been a - the the on good that process, With currently potency that ensuring Thanks our is the application. Baisong. able news very

the that and we include something details. that update to final will With at appropriate and agreed will we regard process be refinements a can you more obviously commercial is time obviously that

Great. color. Thanks for the

question Barclays. is Please next with from Wang Our proceed. Gena

questions. quick three have I you. Thank

to does one remind the a first of expect closed, taking be deal. And guidance transaction cash term impact you is and first the the when us deal that regarding shoreline the is from deal? The to do the and economics, consideration your Can you question.

Thanks, Gena.

You are good. very

them. You That is are great. going to keep

them track to have don’t we all. So

we eligible the of financials those an - is Shoreline commercial deal, the We in did economics. the the with to been the receive - and included regard impact the for milestones with actually assets, actually in the or royalty has the and we future advance that didn’t disclose So the development indeed payments numbers are upfront, considered.

I is that So think the question. first

Okay. Have close payment were the received after or the transaction the show? received you you regarding already

Gena. have received - already the yes have payment We we

your of question, I Yes. actually your which payment. the have we Actually, closed deal, fair Gena, have forgot the received Yes. that is enough. answer part we to

in was payment received The XXXX.

I see.

reported cash the already incorporate So that.

of reported cash include the end yet the that. The at did not year

that -. guidance The Okay. will

That of our reforecast will cash be our runway. in

Okay.

the end Will quick, about timing just RUBY and What there second I question trial update are the present thoughts also Sounds good. on And data like a you also provide of number especially some very ASH. XXX of committed patients? know the you and mid-year. XXXX, to

I’m at both but to planning this answer ask end updates are going of year. question, the the that we Gena, that Thanks, present Yes. to middle year to and this Baisong confirm Baisong. of

Gena middle for Yes, the end will RUBY One data year, question. of the of we the have for year. is released the thanks is plan to the one and Yes, study. two

share In terms of have specific when information. more forum, we will we

And data study the point, a really number shared And this we patient have have multiple earlier mentioned we for momentum we expect release. I study. just the to have as as RUBY for strong but the not patient data well EDITHAL

And programs would beyond explore? lastly, organ then Okay. very your quick, to in-vivo HSC, top be what

use Gena. targets, the we in success. that and of the commercial look targets, will of a ergo to selecting our a a balance of that on for be probability future. We specifics will approach sharing clinical the very tissues. target forward Thanks And of the sort have And factors much, taken multiple and the that state we technology, therapeutic balance actually more of the in our regulatory

you. Thank

much Thanks very

Please question Credit with next proceed. Law Rich is Our from Suisse.

question. my thanks and for taking morning Good

CRISPR/CasX technology you to for So I Since addition companies. CasXX interest focus other have the any from development? follow-up development product on question development, by internal the there in is that. then to in-vivo as life using in renew mature progress a arguably more CasX And is

our to have Rich. advantages. AsCasXXa very said, has actually, believe on currently some I we we it significant We believe in to in actually patients has dosed. that AsCasXXa, now is enzyme we edited pipeline Thanks those say And that Baisong focused addition the have already already much, the also multiple used as have clinic. that

experience a are with clinical actually we So AsCasXXa. building

off-target higher we editing. from and a actually higher position And supporting its believe data that the fidelity advantages that it that point has and with much of efficiency have essentially less

for moving substantial advantages So a forward.

Right.

is broad, in continuously is you licensing CasX product that, to with that you performance with perform there development that to Okay. A question technology? the any agreement follow-up that the have the have requirement

to execution. like on our requirements there And execute. any around development a or ours but conditions obviously, going go not business mixture agreement I’m into to and details, both are are

Great. Okay. you. Thank

Our Kumar Madhu Goldman Please proceed. question is with next Sachs. from

question. medical of thanks the the expect in the for we update, And then we (Ph) for company the on have by seen is about U.S. This taking CRISPR you. how peers? path like in XXXX, Hey, given our you release. two meeting mid or headwinds it do What think quick in-vivo XXX your is should ones. some [Rob] venue Thank regulatory Madhu,

do Baisong, question? second. the you to the first I want take will take

Yes. Sure.

year, data The release the have we as to later the we we the in RUBY venue of specific year. middle not plan decided, So as share of the end well time. will

the I that the regulators. depth on Thanks things experiences, others risk, investment will very expertise from going managing Editas research much, as the what both Baisong. analytics of certainly et of CRISPR, the path me was analytics, in CMC in-vivo regard regulatory to built of comment for cetera. I one as the point And I’m well to its view the substantial that of actually to drew then would say, and say not with

we of to move will actually to view. about forward, we know, from regulators, first-in-human. obviously I determine our as feel, engage we so And very including you FDA with And that good where are, the the path point

Thank you.

much. very Thanks

proceed. Harrison Please from next is Our question Matthew Morgan Stanley. with

for [Chris] questions. on our This (Ph) taking Matthew. for Thanks is

have We package. about SCD filing the two One questions. is

you question it a is an do to second Thank And file XXXX, position think you we see in to possible clinic? to any but a that mentioned be BMS possible the the in think You into times about regulators the talk could and it is you about that, collaboration. Is update progressing XXXX? to the need few of in you. then those programs how should about that

Thanks very much.

me package. let your posture there. both Certainly questions - I think I the take regarding aggressive filing admire

that filings of negotiation required a agencies really negotiations progress only know and timing is and is around what as in we with that question any we the matter is with of something them. will think I

continue regard a actually targets. has nominated driven of progress. BMS. us announcements a to we that from towards are clinic of the to advancing by, lot really BMS and But collaboration driven nice the the regard happy actually With with will We is specifics and that number of collaboration. data the that hope with are received by BMS to the

the we say, excited I very by are As to progress. the collaboration and see delighted

Thank you very much.

Our final question Please is from Liisa Bayko proceed. with Evercore ISI.

has me questions in. thanks but my for all Hi, taking been answered,

Liisa Thanks

you. Thank today’s conclude This will conference.

your for you time this your lines participation. thank disconnect and at may You